Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 617

1.
2.

An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.

Lee YS, Lee KA, Lee JY, Kang MH, Song YC, Baek DJ, Kim S, Kang CY.

Vaccine. 2011 Jan 10;29(3):417-25. doi: 10.1016/j.vaccine.2010.11.005. Epub 2010 Nov 16.

PMID:
21087689
3.

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.

Lindqvist M, Persson J, Thörn K, Harandi AM.

J Immunol. 2009 May 15;182(10):6435-43. doi: 10.4049/jimmunol.0900136.

4.

Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.

Ko SY, Lee KA, Youn HJ, Kim YJ, Ko HJ, Heo TH, Kweon MN, Kang CY.

Eur J Immunol. 2007 Aug;37(8):2127-37.

5.

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.

Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, Boyaka PN, Kim SH, Horimoto T, Kweon MN, Kang CY.

Vaccine. 2007 Jul 9;25(28):5189-98. Epub 2007 May 21.

PMID:
17548137
6.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670.

PMID:
19950232
7.

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.

Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI.

Mucosal Immunol. 2008 May;1(3):208-18. doi: 10.1038/mi.2008.2. Epub 2008 Mar 5.

PMID:
19079180
8.

The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.

Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nakui M, Sekimoto M, Koda T.

Int Immunol. 2000 Jul;12(7):987-94.

PMID:
10882410
9.

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.

Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M.

Vaccine. 2008 Mar 28;26(15):1807-16. doi: 10.1016/j.vaccine.2008.02.002. Epub 2008 Feb 20.

PMID:
18329757
10.

Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.

Asanuma H, Hirokawa K, Uchiyama M, Suzuki Y, Aizawa C, Kurata T, Sata T, Tamura S.

Vaccine. 2001 Jul 16;19(28-29):3981-9.

PMID:
11427274
11.

Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.

Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.

J Med Virol. 2005 Jan;75(1):130-6.

PMID:
15543590
12.

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.

Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2006 Jul;78(7):954-63.

PMID:
16721854
13.
14.

CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus.

Exley MA, Bigley NJ, Cheng O, Tahir SM, Smiley ST, Carter QL, Stills HF, Grusby MJ, Koezuka Y, Taniguchi M, Balk SP.

J Leukoc Biol. 2001 May;69(5):713-8. Erratum in: J Leukoc Biol 2001 Aug;70(2):340.

PMID:
11358978
15.

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.

J Virol. 2005 Mar;79(5):2910-9.

16.

Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.

Patel GB, Zhou H, Ponce A, Chen W.

Vaccine. 2007 Dec 12;25(51):8622-36. Epub 2007 Oct 5.

PMID:
17959279
17.

B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.

Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, Fridman WH, Lemonnier F, Johannes L, Tartour E.

J Immunol. 2007 Sep 1;179(5):3371-9.

19.

α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.

Chuang YH, Wang TC, Jen HY, Yu AL, Chiang BL.

J Immunol. 2011 Apr 15;186(8):4687-92. doi: 10.4049/jimmunol.1003659. Epub 2011 Mar 7.

20.

Supplemental Content

Support Center